61 related articles for article (PubMed ID: 7923563)
1. A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).
Teicher BA
Cancer Metastasis Rev; 1996 Jun; 15(2):247-72. PubMed ID: 8842498
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer.
Jones RB; Matthes S; Dufton C; Bearman SI; Stemmer SM; Meyers S; Shpall EJ
Breast Cancer Res Treat; 1993; 26 Suppl():S11-7. PubMed ID: 8400329
[TBL] [Abstract][Full Text] [Related]
3. CAI: effects on cytotoxic therapies in vitro and in vivo.
Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
[TBL] [Abstract][Full Text] [Related]
4. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
5. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
7. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
8. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase inhibitors - invitro and invivo effects on antitumor alkylating-agents in the emt-6 murine mammary-carcinoma.
Teicher B; Holden S; Ara G; Liu J; Robinson M; Flodgren P; Dupuis N; Northey D
Int J Oncol; 1993 Feb; 2(2):145-53. PubMed ID: 21573528
[TBL] [Abstract][Full Text] [Related]
10. Aging issues in invasion and metastasis. Fertile ground for investigation.
Kohn E
Cancer; 1993 Jan; 71(2 Suppl):552-7. PubMed ID: 8420676
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Teicher BA; Korbut TT; Menon K; Holden SA; Ara G
Cancer Chemother Pharmacol; 1994; 33(6):515-22. PubMed ID: 8137463
[TBL] [Abstract][Full Text] [Related]
12. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue.
Stearns ME; Wang M
Cancer Res; 1993 Feb; 53(4):878-83. PubMed ID: 7679051
[TBL] [Abstract][Full Text] [Related]
13. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.
Teicher BA; Lazo JS; Sartorelli AC
Cancer Res; 1981 Jan; 41(1):73-81. PubMed ID: 7448778
[TBL] [Abstract][Full Text] [Related]
14. The radiosensitivity of a murine fibrosarcoma as measured by three cell survival assays.
Rice L; Urano M; Suit HD
Br J Cancer Suppl; 1980 Apr; 4():240-4. PubMed ID: 6932931
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
